Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, obs

Question

1 year ago

15

ervational, evaluation study. Lancet Oncol. 2021; 22: 98-106

1 answer:

Ghella [55] · Answer 1 · 2024-02-21T21:11:34+03:00

Although stereotactic ablative body radiation (SABR) is being employed to treat oligometastatic malignancies, there is a dearth of high-quality information on which to base public policy.
There is a need for more concrete, real-world evidence.
As the broadest dataset on outcomes in this population to date, the findings of a national study of patients with extracranial oligometastases undergoing SABR are presented here.

<h3>What are the methods followed?</h3>

A prospective, registry-based, single-arm, observational assessment study of patients with solid cancer and extracranial oligometastases treated with SABR was financed by the National Health Service (NHS) England's Commissioning through Evaluation program, which was introduced in 2015.
The recommended doses, which were given in three to eight portions, varied from 24 to 60 Gy. In England, 17 NHS radiation facilities participated in the study.
Patients who were 18 years of age or older, had confirmed primary carcinoma (excluding haematological malignancies), one to three extracranial metastatic lesions, a disease-free gap of more than 6 months between the development of the primary tumor and the development of metastases (apart from synchronous colorectal liver metastases), a WHO performance status of 2 or lower, and a life expectancy of at least 6 months were eligible for the program.
Overall survival at 1 and 2 years after the start of SABR treatment was the main result. The investigation is now over.

<h3>What was interpreted?</h3>

Use of SABR was linked to a high overall survival rate and little harm in patients with extracranial oligometastatic cancer.
The results of the study add to the data from a randomised, phase 2 trial and provide high-level, real-world support for the use of SABR in this patient cohort.
A phase 3 randomised, controlled trial is in underway to confirm these results.
SABR was commissioned by NHS England in March 2020 as a therapy option for patients with oligometastatic illness based on the selection criteria in this study.

To learn more about cancer visit:

#SPJ4